MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that it is accelerating its strategy to enter the Australian Medical Cannabis market, following the indicated regulatory reform by the Federal Government to legalise the use of cannabis for medical purposes and establish a licensed growing program to provide a safe and local source.
MMJ PhytoTech Limited (ASX:MMJ) ("MMJ" or the "Company") is pleased to provide investors with an update on the progress at its Duncan facility in Canada.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that it will be featured in an upcoming episode of Innovations with Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. Dates and show times to be advised.
MMJ PhytoTech Limited (ASX:MMJ) (the "Company") advises that APP Securities Pty Ltd has issued an updated research report which is available on the Company's website
MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that its Swiss-based subsidiary Satipharm generated the Company's first revenues from sales of its game-changing CBD (Cannabidiol) Capsules in the month of August. The Company also announces the official launch of Satipharm.com, where retail customers in the European Union (the "EU") can purchase the Capsules today.
MMJ PhytoTech Limited (ASX:MMJ) is pleased to announce that its subsidiary, PhytoTech Therapeutics, has received official National approval in Israel to commence a Phase I Clinical Study to assess the safety and performance of its proprietary oral capsule formulations.
PhytoTech Medical Limited (ASX:PYL), is pleased to announce that it has completed the acquisition of 100% of the issued capital of MMJ Bioscience Inc. (MMJ). Shareholder approval was received on 29 June 2015 and all regulatory approvals have been satisfied to allow for the completion of the transaction.
